RxDoctor Payments Data

Sudha Kodali

Internal Medicine · Houston, TXNPI 1154512333

Payments from drug & device makers

$746,036in general payments, 2019–2025

Across 471 payments — averaging $1583.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$625K
  • Gilead$55K
  • AstraZeneca$37K
  • Madrigal Pharmaceuticals$10K
  • Sirtex Medical Inc$7K
  • Boston Scientific$7K
  • plus $5K from 33 others

What the payments were for

  • Consulting fees$24,94428%
  • Speaking & faculty fees$41,46547%
  • Grants$3,1254%
  • Travel & lodging$6,9658%
  • Food & beverage$10,88512%
  • Education$2390%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$746,036 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$85,019
Medicare patients
352
Services billed
701

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin174$561,090
EpclusaSofosbuvir/Velpatasvir14$340,709
OcalivaObeticholic Acid12$112,131
RezdiffraResmetirom11$68,796
VemlidyTenofovir Alafenamide33$46,465
Ursodiol106$15,925
Lactulose72$3,694
Tenofovir Disoproxil Fumarate11$3,193
Mycophenolate Mofetil26$3,094
Entecavir28$2,333
ConstuloseLactulose31$1,335
Spironolactone78$904
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates11$612
Amiloride Hcl18$449
Furosemide70$363

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$893$561,090174 claims
GileadEpclusa, Vemlidy$54,726$387,17447 claims
Intercept Pharmaceuticals, Inc.Ocaliva$463$112,13112 claims
Madrigal PharmaceuticalsRezdiffra$9,739$68,79611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →